Sept 17 (Reuters) - Women's telehealth provider Wisp

said on Wednesday it has expanded its weight-care offerings to

include sale and doorstep delivery of Novo Nordisk's

and Eli Lilly's ( LLY ) wildly popular drugs without the need

for insurance.

Telehealth firms, along with the two drugmakers,

pharmacies, and other related entities, have launched several

direct-to-consumer offerings to tap into the extraordinary

demand for weight-loss drugs.

New York-based Wisp said it has priced Ozempic, Wegovy,

and Mounjaro at $598, $558, and $489 per month, respectively,

with the cost also including consultation, monthly follow-ups,

and direct-to-door delivery.

U.S. list prices for Novo Nordisk's Wegovy and Eli

Lilly's ( LLY ) Zepbound are about $1,000 per month or more. But both

companies offer a monthly supply for $499 to

customers paying cash

instead of using health insurance.

"Our cash-pay model particularly benefits those who would

otherwise face high out-of-pocket costs or who wouldn't qualify

for coverage of GLP-1s," CEO Monica Cepak told Reuters in an

email.

Wisp, majority-owned by Canada-based digital healthcare firm

WELL Health Technologies ( WHTCF ), launched its weight care

vertical in 2024, initially addressing hormonal imbalances from

conditions like PCOS and menopause. The telehealth firm plans

further expansion into at-home diagnostics and menopause care.

Other telehealth providers offering GLP-1 medications

include Hims & Hers, LifeMD ( LFMD ), Teladoc Health ( TDOC )

, Ro, and Noom Med, many of which partner with

drugmakers to provide FDA-approved treatments alongside health

coaching and weight management support.